Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO

Dr. Stephen M. Hahn, former FDA Commissioner (2019–2021), has been appointed chief executive officer at Nucleus RadioPharma, a contract development and manufacturing organization specializing in radiopharmaceuticals135.

Prior to this appointment, Hahn was CEO-partner at Flagship Pioneering and CEO of Harbinger Health since 20211.

He brings extensive regulatory, clinical, and operational leadership experience, having also served as chief medical executive at MD Anderson Cancer Center in Houston13.

The appointment signals a push to scale up infrastructure for patient access to minimally invasive, targeted radiopharmaceutical cancer therapies, which promise fewer side effects and greater precision13.

Industry challenges include limited supply and manufacturing capacity for key medical isotopes and underdeveloped operations for managing radioactive drugs, making Hahn’s expertise especially relevant1.

Nucleus RadioPharma focuses on overcoming these logistical barriers to unlock greater access to advanced cancer treatments13.

Sources:

1. https://www.biospace.com/press-releases/nucleus-radiopharma-appoints-former-fda-commissioner-dr-stephen-hahn-as-ceo-to-scale-patient-access-to-radiopharmaceutical-therapies

3. https://www.statnews.com/2025/08/20/nucleus-radiopharma-stephen-hahn/

5. https://www.fundz.net/executives/nucleus-radiopharma-hired-964f